MSN Labs Americas SAS Pharmaceutical Import Profile — Colombia (DGFT 2022–2026)

Name: MSN Labs Americas SAS Pharmaceutical Import Records from India — 3 Products, $2.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

MSN Labs Americas SAS — Pharmaceutical Importer Profile (2026) | 3 Products, $2.4M Trade | TransData Nexus

MSN Labs Americas SAS

Pharmaceutical Importer · Colombia · Cardiovascular Focus · $2.4M Total Trade · DGFT Verified

MSN Labs Americas SAS is a pharmaceutical importer based in Colombia with a total trade value of $2.4M across 3 products in 3 therapeutic categories. Based on 87 verified import shipments from Indian Customs (DGFT) records, MSN Labs Americas SAS is the #1 buyer in 1 product including Pomalidomide. MSN Labs Americas SAS sources from 1 verified Indian supplier, with Msn Laboratories Private Limited accounting for 100.0% of imports.

MSN Labs Americas SAS — Import Portfolio & Supplier Network

MSN Labs Americas SAS import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to MSN Labs Americas SAS?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Msn Laboratories Private Limited	$13.9M	574	100.0%

MSN Labs Americas SAS sources from 1 verified Indian supplier across 391 distinct formulations. The sourcing is highly concentrated — Msn Laboratories Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Dismigras 40 rosuvastatin 40MG 3x10 as per	$286.3K	9
Dismigras 40 (rosuvastatin 40 MG)	$200.0K	4
Renangio 80 (telmisartan 80MG)	$169.3K	4
Renangio plus 80+12.5 (telmisartan + hydrochlorothiazide 80+12.5)	$165.5K	11
Apritant iv fosaprepitant 150 MG 1s	$164.8K	5
Apritant iv(fosaprepitant150mg)1's	$164.2K	4
Epnone 25(eplerenone 25MG	$153.9K	4
Apritant iv(fosaprepitant 150MG)1s	$153.4K	4
Apritant iv (fosaprepitant 150MG) 1s	$150.0K	3
Thaladef 360 MG (3 x 10's)	$150.0K	3
Macitent (macitentan 10MG) (3 x 10's)	$150.0K	3
Abirand 250 (abiraterone acetate tablets250mg) 1 x	$150.0K	3
Ferasiro 500 (deferasirox 500MG)	$150.0K	3
Apritant iv (fosaprepitant 150MG) 1's	$150.0K	3
Epibalin 75 (pregabalin 75MG)	$123.2K	10

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Telmisartan	Cardiovascular	$1.8M	64	0.0%	16
2	Voriconazole	Advanced Antifungals	$424.7K	20	1.4%	11
3	Pomalidomide	Advanced Oncology	$150.0K	3	3.4%	1

MSN Labs Americas SAS imports 3 pharmaceutical products across 3 categories into Colombia totaling $2.4M. The company is the #1 buyer for 1 product: Pomalidomide.

MSN Labs Americas SAS — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

MSN Labs Americas SAS is a pharmaceutical importer and distributor based in Bogotá, Colombia. Established in August 2016, it operates as a wholly owned subsidiary of MSN Laboratories Private Limited, a prominent Indian pharmaceutical company. The Colombian branch serves as the regional office for MSN Laboratories across 15 Latin American countries, providing support and coordination for their operations in the region.

The company's primary focus areas include oncology, cardiovascular treatments, anti-diabetic therapies, central nervous system (CNS) disorders, and urology. MSN Labs Americas SAS has successfully launched generics and branded products that have become category leaders in Colombia, such as Lacosamide, Silodosin, and Fosaprepitant.

2Distribution Network

MSN Labs Americas SAS operates from its office located at Edificio 128, Centro Empresarial P.H., Carrera 7N 127-48 Of 302, Bogotá, Colombia. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in Bogotá suggests a centralized distribution model. This centralization likely facilitates efficient logistics and supply chain management, enabling the company to serve the Colombian market effectively.

3Industry Role

In Colombia's pharmaceutical supply chain, MSN Labs Americas SAS functions primarily as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from its parent company in India, it plays a crucial role in introducing and distributing a range of generic and branded medications within the Colombian market. The company's focus on therapeutic areas such as oncology, cardiovascular, and anti-diabetic treatments positions it as a significant player in addressing the healthcare needs of the Colombian population.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — MSN Labs Americas SAS

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

MSN Labs Americas SAS demonstrates a high degree of supplier concentration, sourcing all its pharmaceutical imports from MSN Laboratories Private Limited in India. This single-source dependency indicates a strategic choice to leverage the established relationship and product portfolio of its parent company. The stability of this relationship is evidenced by the consistent importation of 87 shipments totaling $2.4 million USD over the period from 2022 to 2026. The top three imported products—Telmisartan, Voriconazole, and Pomalidomide—account for 100% of the company's imports, reflecting a focused product strategy.

2Supply Chain Resilience

The resilience of MSN Labs Americas SAS's supply chain is closely tied to its exclusive reliance on MSN Laboratories Private Limited in India. While this centralized sourcing strategy offers streamlined operations and potential cost efficiencies, it also exposes the company to risks associated with geopolitical events, regulatory changes, and logistical disruptions in India. The lack of backup suppliers and limited formulation diversity may pose challenges in maintaining a continuous supply of products. Additionally, the company's dependence on a single supplier for all imported formulations may impact its ability to adapt to changing market demands or regulatory requirements.

Importing Pharmaceuticals into Colombia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Colombia

1Regulatory Authority & Framework

In Colombia, the primary regulatory authority overseeing pharmaceutical imports is the National Institute for Food and Drug Surveillance (INVIMA). INVIMA is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products entering the Colombian market. Key legislation governing pharmaceutical imports includes Decree 677 of 1995, which outlines the sanitary registration requirements for drugs and biological products. This decree mandates that all pharmaceutical products must obtain sanitary registration from INVIMA before being marketed in Colombia. (serviciolegal.com.co)

2Import Licensing & GMP

Importers in Colombia must be legally registered with the National Tax and Customs Directorate (DIAN) and possess a Tax Identification Number (NIT). Registration with the Single Window for Foreign Trade (VUCE) platform is also mandatory. For pharmaceutical products, obtaining prior approval from INVIMA is required, which involves submitting a dossier that includes Good Manufacturing Practice (GMP) compliance certificates, stability data, and labeling in Spanish. Additionally, importers must appoint a local sanitary representative (titular sanitario) to act as a liaison with INVIMA.

Quality & Labeling

MSN Labs Americas SAS — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

MSN Labs Americas SAS's product strategy focuses on therapeutic areas with significant market demand in Colombia, including cardiovascular treatments, advanced antifungals, and advanced oncology therapies. The company's import portfolio is heavily weighted towards cardiovascular products, particularly Telmisartan, which accounts for 75.6% of its imports. This focus aligns with the high prevalence of cardiovascular diseases in Colombia and the need for effective treatment options. The inclusion of advanced antifungals and oncology products addresses critical healthcare needs, reflecting the company's commitment to providing comprehensive therapeutic solutions.

2Sourcing Profile

MSN Labs Americas SAS's sourcing strategy is centered on importing finished pharmaceutical formulations from its parent company, MSN Laboratories Private Limited in India. This approach leverages the established manufacturing capabilities and product portfolio of MSN Laboratories, ensuring a consistent supply of high-quality medications. The focus on finished formulations, rather than active pharmaceutical ingredients (APIs), indicates a strategic decision to streamline operations and reduce the complexities associated with API sourcing and manufacturing.

3Market Positioning

Seller's Guide — How to Become a Supplier to MSN Labs Americas SAS

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Colombian market by establishing partnerships with MSN Labs Americas SAS. To capitalize on this opportunity, Indian exporters should focus on understanding the specific product requirements and quality standards mandated by INVIMA and other Colombian regulatory authorities. Demonstrating compliance with these standards and building a strong relationship with MSN Labs Americas SAS can facilitate market entry and expansion.

2Requirements & Qualifications

Indian exporters seeking to supply MSN Labs Americas SAS and the Colombian market must ensure that their products meet the regulatory requirements set by INVIMA. This includes obtaining GMP certificates recognized by INVIMA, providing stability data, and ensuring that labeling is in Spanish and complies with Colombian regulations. Additionally, exporters must be prepared to appoint a local sanitary representative in Colombia to act as a liaison with INVIMA and facilitate the registration process.

3How to Approach

Frequently Asked Questions — MSN Labs Americas SAS

What products does MSN Labs Americas SAS import from India?

MSN Labs Americas SAS imports 3 pharmaceutical products across 3 categories. Top imports: Telmisartan ($1.8M), Voriconazole ($424.7K), Pomalidomide ($150.0K).

Who supplies pharmaceuticals to MSN Labs Americas SAS from India?

MSN Labs Americas SAS sources from 1 verified Indian suppliers. The primary supplier is Msn Laboratories Private Limited (100.0% of imports, $13.9M).

What is MSN Labs Americas SAS's total pharmaceutical import value?

MSN Labs Americas SAS's total pharmaceutical import value from India is $2.4M, based on 87 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does MSN Labs Americas SAS focus on?

MSN Labs Americas SAS imports across 3 categories. The largest: Cardiovascular (75.6%), Advanced Antifungals (18.0%), Advanced Oncology (6.4%).

Get Full MSN Labs Americas SAS Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.